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nostic information can be extracted by leveraging artificial intelligence (AI) for treatment monitoring,
superior and complementary to the current response evaluation methods. Methods: To test this, a co-
hort of 74 stage-IV urothelial cancer patients (37 in the discovery set, 37 in the independent test, 1087
CTs), who received anti-PD1 or anti-PDL1 were retrospectively collected. We designed an AI system
[named prognostic AI-monitor (PAM)] able to identify morphological changes in chest and abdominal
CT scans acquired during follow-up, and link them to survival. Results: Our findings showed significant
performance of PAM in the independent test set to predict 1-year overall survival from the date of image
acquisition, with an average area under the curve (AUC) of 0.73 (p < 0.001) for abdominal imaging, and
0.67 AUC (p < 0.001) for chest imaging. Subanalysis revealed higher accuracy of abdominal imaging
around and in the first 6 months of treatment, reaching an AUC of 0.82 (p < 0.001). Similar accuracy was
found by chest imaging, 5-11 months after start of treatment. Univariate comparison with current mon-
itoring methods (laboratory results and radiological assessments) revealed higher or similar prognostic
performance. In multivariate analysis, PAM remained significant against all other methods (p < 0.001),
suggesting its complementary value in current clinical settings. Conclusions: Our study demonstrates
that a comprehensive AI-based method such as PAM, can provide prognostic information in advanced
urothelial cancer patients receiving immunotherapy, leveraging morphological changes not only in tumor
lesions, but also tumor spread, and side-effects. Further investigations should focus beyond anatomical
imaging. Prospective studies are warranted to test and validate our findings.
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Background: Immune checkpoint inhibitor efficacy in advanced cancer patients remains
difficult to predict. Imaging is the only technique available that can non-invasively provide
whole body information of a patient’s response to treatment. We hypothesize that
quantitative whole-body prognostic information can be extracted by leveraging artificial
intelligence (AI) for treatment monitoring, superior and complementary to the current
response evaluation methods.
Methods: To test this, a cohort of 74 stage-IV urothelial cancer patients (37 in the
discovery set, 37 in the independent test, 1087 CTs), who received anti-PD1 or anti-PDL1
were retrospectively collected. We designed an AI system [named prognostic AI-monitor
(PAM)] able to identify morphological changes in chest and abdominal CT scans acquired
during follow-up, and link them to survival.
Results: Our findings showed significant performance of PAM in the independent
test set to predict 1-year overall survival from the date of image acquisition, with an
average area under the curve (AUC) of 0.73 (p < 0.001) for abdominal imaging, and 0.67
AUC (p < 0.001) for chest imaging. Subanalysis revealed higher accuracy of abdominal
imaging around and in the first 6 months of treatment, reaching an AUC of 0.82 (p
< 0.001). Similar accuracy was found by chest imaging, 5–11 months after start of
treatment. Univariate comparison with current monitoring methods (laboratory results
and radiological assessments) revealed higher or similar prognostic performance. In
multivariate analysis, PAM remained significant against all other methods (p < 0.001),
suggesting its complementary value in current clinical settings.
Conclusions: Our study demonstrates that a comprehensive AI-based method such as
PAM, can provide prognostic information in advanced urothelial cancer patients receiving
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immunotherapy, leveraging morphological changes not only in tumor lesions, but also
tumor spread, and side-effects. Further investigations should focus beyond anatomical
imaging. Prospective studies are warranted to test and validate our findings.
Keywords: artificial intelligence, immunotherapy, checkpoint inhibitors, urothelial cancer, treatment monitoring,
imaging - computed tomography, response assessment, prognostication
INTRODUCTION
Durable clinical benefit to immune checkpoint inhibitors in
metastatic setting led to approval in several malignancies (1–3).
Unlike traditional cancer treatments, such as chemotherapy and
radiotherapy, which are administered for a predefined amount
of time, immunotherapy is generally administered until there
are tangible clinical benefits or until progressive disease/adverse
events deem it unsuitable—for a maximum of 2 years. To achieve
this, an accurate treatment evaluation method is required.
Whole-body Computed Tomography (CT) provides
information on the full-picture of the patient. Beyond tumor
size dynamics, CT imaging allows assessment of immune-related
side-effects and/or disease-related complications.
Therapy response evaluation following CT is measured
according to the response evaluation criteria in solid tumor
(RECIST) (4), or iRECIST, adapted for immunotherapy (5). This
involves prospective tracking of preselected lesions by measuring
2-dimensional diameters. Various immune-related toxicities and
cancer-related complications that inform clinical practice may
also be identified on CT scans, but are not accounted for in
current RECIST criteria. So far, a comprehensive quantitative
approach that involves quantitative response evaluation and
clinically relevant conditions is lacking.
Quantitative approaches, such as radiomics, have been
explored in the past (6, 7). While these led to satisfactory
results in the field of prognostication, these rely mostly on
manual segmentations, which are time-consuming and prone to
human operator error. A comprehensive non-invasive method
that comprises the assessment of tumor size dynamics and side-
effects or other cancer-induced conditions, in an automatic and
precise quantitative manner, would be preferable.
Novel techniques of computational imaging and artificial
intelligence (AI) can be the basis for quantitative methods for
treatment monitoring (8). Specifically, AI algorithms can be
seen as methods to capture, measure, and quantify complex
highly-variable anatomical phenomena for prognostic purposes,
in a robust and time-efficient manner. To this end, we
have developed an AI algorithm that performs automated
tracking and quantification of morphological changes based on
longitudinal CT imaging in immunotherapy treated patients,
allowing correlations with overall survival. We term our AI
system the Prognostic AI-monitor (PAM). Recently, a similar
pilot approach was tested in a study on chest imaging of a
NSCLC cohort (8), demonstrating accurate response prediction
and a correlation with overall survival. In this study, we aim
to extend the model to thoracoabdominal imaging, and validate
it on a cohort of metastatic urothelial cancer patients treated
with anti-PD1/PDL1. The model accuracy will be assessed at
various time points within the treatment timeline, and the




We retrospectively included stage-IV urothelial cancer patients
treated with anti-PDL1 or anti-PD1 monotherapy that had
started follow-up imaging at the Netherlands Cancer Institute -
Antoni van Leeuwenhoek hospital (NKI-AVL, Amsterdam, The
Netherlands) between 07-2014 and 06-2018. Response evaluation
was done using regular contrast-enhanced CT scans of the
abdomen, chest, or both. For all patients, CT imaging scans
acquired between 6 months prior to the start of immunotherapy,
up to 2 years after, were collected. Inclusion criteria were high-
resolution images (slice thickness ≤ 5mm), and the presence
of at least thorax or abdomen in the scan field. As we aim
to use AI to track changes across follow-up, patients with <
2 scans, at two different time points, could not be included.
These criteria were verified automatically via the DICOM tag,
or via the automatic localization algorithm proposed by Zhang
et al. (9), respectively. For each patient, we recorded age at
start of treatment, date of start of treatment, and date of
death. Additionally, to compare PAM with current treatment
monitoring standards, we collected parameters of radiological
assessments (progression and response), as well as routine clinical
blood analyses (hemoglobin, leukocyte count, thrombocyte
count, and erythrocyte count). The entire dataset was divided
into discovery and an independent test set based on the patients’
ID (even IDs were assigned to the discovery set, odd IDs were
assigned to the independent test set, creating a 50/50 split). The
study was conducted at the NKI-AVL after approval of the local
Institutional Review Board (IRBd19-083).
Data Harmonization
A data harmonization protocol was applied to mitigate
heterogeneity from typical real-world imaging datasets. This
consisted of isotropic linear resampling of the scans at 2mm,
clipping of the Hounsfield units between−120 (fat) and 300
(cancellous bone), and rescaling of the intensities between 0 and
1. All images were cropped and padded to 192× 192× 192 voxels
(160 axial coordinate for chest imaging).
Prognostic AI-Monitor
PAM is composed of three AI-modules. The first module, termed
localizer, consisted of a VGG-like convolutional network, tasked
to crop out the chest and the abdomen in two separate images,
each according to standardized anatomical locations. These were
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defined as the space between the lower neck and the lower
diaphragm, and the space between the upper diaphragm and the
lower pelvis, respectively. The second and third modules, termed
trackers, consisted of two instances of the same convolutional
network, one trained for chest imaging, and one for abdominal
imaging, tasked to quantify morphological changes between pairs
of images. We termed these modules the chest and abdominal
tracker, respectively. Their architecture was based on radiological
deep learning-based image-to-image registration. At its core,
each tracker is tasked to match anatomical landmarks and
shapes of two 3D radiological images. In doing so, the network
learns to quantify anatomical differences between pairs of scans.
We leveraged the tracker network knowledge (i.e., its latent
representation) to extract quantitative imaging feature vectors
representing morphological changes between follow-up scans of
the same patient, and fed them into a classifier trained to predict
survival. Time from start of treatment, and time between scans
were also fed into the classifier, for temporal reference.
Localizer Module
The localizer module was designed following the research of
Zhang et al. (9). The authors showed how a convnet trained
to sort slices in a specific order (e.g., from head to toe) can be
used for anatomical localization. The network followed a siamese
learning scheme. It received a pair of CT slices from a single
scan, and had to learn which of the two slices would be on
top of the other in the original CT scan. The only way for the
network to learn to perform this task would be for the network to
assign to each anatomical location a number i that would increase
from head to toe. Once the training was complete, we used the
network to retrieve a specific location by searching for their
assigned number (for example, in our case, the upper-most point
of the diaphragm was always assigned to be around i = 25). This
algorithm idea is particularly powerful, as the ground truth (i.e.,
the order of the slices) can be automatically extracted from the
CT scan, and therefore it does not require any manual labeling.
Our localizer module was built largely based on Zhang’s
architecture design — the exact architecture we used is shown in
Figure 1A. The network was trained following the same siamese
learning scheme of the original research (9). Binary cross-entropy
was the loss function chosen, the optimizer was Adam with an
initial learning rate of 0.001, and the batch size was set to 8
(i.e., 8 random scans, one random pair of slices per scan). As it
was difficult to set a number of epochs (considering it could be
based either on the number of scans or on the number of slices),
we chose to set a general number of iterations, namely 50,000.
RANSAC regression (10) was used to model the relation between
the network score and the actual slice number for each scan. We
chose RANSAC for its robustness to irregularities provided by
the localizer algorithm. Figure 1B shows the localizer network
applied to a scan.
Tracker Module
The tracker module was designed following the research of
Balakrishnan et al. (11) and Zhao et al. (12), as well as our
previous work on chest imaging in NSCLC (8). The network
receives two images as input (i.e., a moving and fixed one)
concatenated along the channel axis. The architecture of the
network processes the input in two subsequent parts. The first
part, consisting of VGG-like convnet, parses the images through
a series of five subsequent convolutional blocks and two fully
connected layers, to regress the 12 parameters of the affine
transform. This is used to give a linear pre-alignment between
the input images, correcting for different patient positions. The
second part of the network follows a U-Net architecture (13),
where the inputs (i.e., the affine warped moving image and the
fixed image) are processed together to regress a displacement
field. The displacement field specifies for each voxel a 3D
vector. The vector indicates where the voxel in that location
of the moving image would be displaced to, in order to match
the corresponding anatomical structure in the fixed image.
This part of the network consisted of an encoder with four
convolutional blocks downsampling the images by half the
size via striding, a convolutional latent space with stride of
one, and four deconvolutional blocks each upsampling the
inputs by double the size via striding. Skip connections were
implemented between encoding and decoding layers following
the implementation in the original paper. Both affine and
deformable parameters are applied to the moving image through
a spatial transformation layer.
The network was trained to minimize the correlation
coefficient loss (11, 12). Three penalties were also employed to
mitigate for unlikely morphological deformations: two on the
affine loss (weighted 1/10), and one on the deformable loss
(weighted 1/100). We decided to decrease the weight on the
deformable loss to give to the model more freedom in modeling
abdominal changes. Adam optimizer was used during training,
with an initial learning rate of 3 × 10−4. A curriculum learning
scheme was implemented during training, such that the loss
would be computed on a decreasingly smoother version of the
images. The smoothing was implemented via average pooling,
starting with a kernel size of 9, and reduced by 3 at epochs 100,
150, and 175. Batch size was set to 2. To mitigate negative effects
resulting from the small batch size, group normalization was
employed instead of batch normalization (14). Figure 2A shows
a detailed overview of the model and the loss used.
Both the localizer and trackers were unbiased toward both
cancer and treatment, and could be trained on unlabeled data.
Using The Cancer Imaging Archive (TCIA) (15), we collected1
all available radiological images, and excluded scans with non-
axial acquisition, low resolution (> 5mm), animals (e.g., mice,
suine) and phantoms. Based on thorax-abdominal CT scans, we
then trained the localizer module on a lymphadenopathy dataset
and extracted abdomen slices from all archived CT scans. Next,
the isolated set of abdominal CT scans (16–35) were employed to
train the abdominal tracker PAM module. We kept a 10% hold
out during training to control for overfitting (i.e., patients whose
ID were multiples of 10 were held out). At each training iteration,
we created a batch by randomly sampling pairs of TCIA’s
abdominal CT scans. This implies that the network learned,
in principle, to register pairs (likely) composed of scans from
different patients, or even different datasets. This auxiliary task
1Accessed on the 21st of April 2020.
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FIGURE 1 | (A) Schematic representation of the localizer architecture and its training. The CT slices in input are axial slices taken from the same CT scan. Z1 and Z2
are the axial coordinates of each input slice, respectively. The red square symbolizes the binary cross entropy loss function used during training. (B) A use-case of the
localizer. Each axial slice is processed through the network to generate a score. A linear relation between the scores and the axial coordinate is estimated. Cropping of
the thorax and abdomen is done based on the anatomical scores, and corresponding axial slice.
represents a more complex problem than the one of matching
follow-up scans of the same patient. Our goal was for the AI to
learn to match corresponding imaging landmarks, and to cover a
large set of possible variations while, simultaneously, containing
its scope (or prior knowledge) to landmarks in the abdominal
area. For the chest AI tracker module, we leveraged the trained
weights from the NSCLC study (8). The code of both tracker and
localizer have been added to the department AI repository2.
Association With Survival
In order to predict survival, we trained a logistic regression
classifier based on the quantitative features extracted from the
tracker. More specifically, we leveraged the feature maps in the
deepest layer of the U-Net (this is shown in Figure 2A). To obtain
2Github: github.com/nki-radiology/PAM.
a feature vector that can be used for the standard logistic classifier,
we applied global average pooling. The resulting feature vector
(96 entries or features) was fed into the logistic regression model
to predict whether the patient would die within 1 year after the
date of the latter scan, see Figure 2B. For simplicity, the higher
resolution information flow in the skip layers and in the final
deformation field were not utilized for prognostication. Time
from start of treatment, and time between scans were also fed
into the classifier, for temporal reference. For each patient, we
employed any two scans that were at most 1 year apart from
each other.
Comparison to Clinical Standards for
Monitoring
We compared PAM against radiological assessments and blood
values. For simplicity, we limited the analysis to PAM-scores
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FIGURE 2 | (A) Schematic representation of the tracker architecture and its training. (B) Use case of the tracker within PAM.
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of abdominal imaging. We employed both univariate and
multivariate comparison. The large majority of scans included in
the analysis of PAM did not have a corresponding radiological
assessment, or blood exam done on the same day — in other
words, there was no one-to-one matching for the majority of
the cases. To overcome this limitation, we averaged the values
of both radiological assessments and blood work over a window
of 6 weeks, centered on the date of the CT scan analyzed by
PAM. Since PAM leverages tracking of morphological changes,
we applied the same principle to the blood values. Namely, we
estimated the rate of change of each blood value over time, i.e.,
(vs – vp)/dt, where vp and vs is the blood values at prior and
subsequent scan, respectively, and dt is the time in between.
Radiological progression and response were assessed based
on an increase in diameter of 20% or decrease of 30%
in diameter, respectively, according to RECIST standards.
Diameters were derived using d = 3√(6V/π), where V is
the tumor volume delineated by a radiologist (PA). As these
assessments already represented longitudinal change, they were
left untouched, allowing for the creation of two classes
(i.e. “response” and “progression”).
Prognostic Heatmaps
In order to interpret the results from PAM, we employed an
occlusion sensitivitymethod (36).With this method, we occluded
a section (or patch) of the image to the AI, by setting its voxel
intensities to zero. We collected the prediction made by the AI
on the occluded image, and compared it with the prediction on
the original image. The importance of that patch was defined
as the absolute difference between the predictions made on the
occluded and the prediction made on the original image. A
heatmap was generated by scrolling the occluded patch through
the image, and collecting the relative importance of each patch.
We termed the resulting visualization the prognostic heatmap.
The pseudo-code of the algorithm is presented in Algorithm 1.
A board-certified radiologist (TNB, specialized in thoracic and
abdominal oncologic imaging, blinded to the outcome) was
tasked to visually analyse the prognostic maps for a subcohort of
the validation set. These were patients that had both thoracic and
abdominal imaging. We chose the first available scan pair closest
to the start of treatment — namely baseline and first follow-up.
The radiologist was tasked to identify the location of highlights
on the heatmaps, as well as pathologies/anomalies that were
not highlighted, i.e., “hotspots” and “coldspots,” respectively.
Expert assessments were categorized based on whether they were
hotspots or coldspots. This resulted in three classes of interest:
hotspots on tumor lesions or therapy-related lesions, hotspots
on seemingly healthy parenchyma, and coldspots on tumor or
therapy-related lesions. Coldspots on healthy tissues are trivial,
and therefore not accounted for.
Statistical Analysis
PAM aims to predict whether the patient will die within 1
year after the date of the latter scan. As this is done through
a classification system, we evaluated the performance of the
model using classical classification statistics. Namely, we assessed
specificity, sensitivity, and area under the receiver operating
Algorithm 1 | A1. Generation of Heatmaps for Model Explainability.
Input (prior, subsequent, time_start, time_delta)
1 Reference_score← PAM(prior, subsequent, time_start, time_delta)
2 ROI← (0:64, 0:64, 0:64) [A]
3 Occluded_prior, Occluded_subsequent← copy (prior), copy
(subsequent)
4 Occluded_prior[ROI], Occluded_subsequent[ROI]← 0, 0
5 Occluded_score← PAM(occluded_prior, occluded_subsequent,
time_start, time_delta)
6 ROI_importance← |occluded_score - reference_score|
7 Prognostic_map[ROI]← maximum (prognostic_map[ROI],
roi_importance) [B]
8 Move the ROI 8 voxels along one of the axis
9 If ROI has not scrolled through the whole image yet, go to Step 3
10 Return prognostic_map
[A] cube of 64 × 64 × 64 in the top left back corner, [B] since the ROI are overlapping,
we chose to use the maximum function, which prevents erroneous overriding of
previous estimation.
curve (ROC-AUC). Statistical significance was assessed using
the Mann-Whitney-U test. Confidence intervals were estimated
via bootstrapping performed using sampling with replacement
(1,000 times). Statistical comparison between ROC-AUC was
performed via McNeils’ test. Multiple hypothesis testing was
corrected with the false discovery rate (FDR) method with alpha
set at 10%. A generalized multivariate linear regression was
employed to evaluate the significance of PAM against current
clinical standards (radiology and blood work).
RESULTS
Study Cohort
A total of N = 103 patients were included in this study. Ten
patients had only one scan available, making it impossible to
model longitudinal changes, and therefore had to be excluded
from the analysis. Nineteen patients did not have enough time
between imaging date and censor date, and were excluded (see
Figure 3A). The median age in this cohort was 65 years (IQR: 55
— 72). Upon stratification, N = 37 patients were assigned to the
training set, and N = 37 in the validation set. In terms of overall
survival, the median was reached in about 1 year (345 days).
Imaging-wise, we included a total of N = 1,087 CT scans
between 6 months before start of treatment and up to 2 years
after. These were used to create the scan pairs needed for PAM
to model morphological changes. In total, we found N = 2,339
abdominal, and N = 7,431 chest scan pairs. We further excluded
all scan pairs of living patients whose time between the latest
scan and censor was < 1 year, and whose time between scans
in the scan pair was more than 1 year. This resulted in N =
1,209 abdominal scan pairs, andN = 3,701 chest scan pairs in the
discovery set and N = 614 and N = 1,937, in the validation set,
respectively.We chose not to limit the analysis to only subsequent
scans, as the time points of when they were taken, and the time
interval between them might vary. We rather chose to include all
feasible pairs, within a given time-interval.
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FIGURE 3 | (A) Consensus, (B) PAM Abdominal tracker performance compared to other standard factors used for treatment monitoring. Significance levels are
reported for p < 0.001 (***), 0.01 (**), 0.05 (*), 0.1 (·) and n.s. for non-significant (C) PAM Abdominal and Thoracic monitoring performance, over time, with respect to
the start of treatment, in weeks. The | indicates statistical significance after FDR correction (D) Example of the prognostic heat map overlaid on top of the original
abdominal scan.
With respect to the unlabelled data used for training, we
retrieved a total ofN = 37,573 CT scans fromTCIA. The localizer
was trained first, on N = 176 thoracoabdominal CT scans from
the lymphadenopathy dataset. The abdominal tracker was trained
on N = 3,137 abdominal CT scans, resulting from the automatic
inclusion procedure.
Prognostic Performance
We assessed the ability of the classifier (trained on the imaging
features of the tracker module) to predict 1 year survival after the
latter scan of the scan pair. Across all scan pairs and treatment
course (up to 6 months before and 2 years after start of therapy),
the overall performance on the independent validation set was
0.73 AUC (CI: 0.69–0.76, p < 0.001) for abdominal images, and
0.67 AUC (CI: 0.64–0.69, p < 0.001) for chest images. Specificity
and sensitivity were 0.74 (CI: 0.69–0.80) and 0.60 (CI: 0.56–
0.64) for abdominal images; and 0.71 (CI: 0.68–0.74) and 0.58
(0.56–0.60) for chest images, respectively.
This results gives us an overview of the performance of PAM,
independently from the treatment time point or interval between
follow-up scans. To gain additional insights in the performance
of PAM at different treatment time points, we employed a
temporal analysis of the performance on a 6-months moving
window. Particularly, we estimated the performance of PAM for
all pairs acquired between day d and d+ 6months, with dmoving
forward by 7 days at each step. The analysis was run on temporal
windows with at least 10 positive and 10 negative samples to limit
statistical noise. For abdominal scans, the highest prognostic
performance was reached in the first 6 months of treatment (7–
189 days), with an ROC-AUC of 0.82 (CI: 0.72–0.89, P < 0.0001).
In general, the temporal windows around and up to the first 8
months of treatment seem to be the ones carrying the highest
predictive value, staying significant after correction for multiple
hypothesis testing. Similar results were obtained for chest scans.
The highest prognostic performance was reached later than the
abdominal model, around 5–11 months after start of treatment,
with a ROC-AUC of 0.83 (CI: 0.71–0.92, P = 0.0002). Unlike
abdominal scans, which were observed to have a prognostic value
both around and during treatment, chest scans carried much
higher prognostic value during treatment rather than around the
start date. Detailed results of the prognostic performance over
time are shown in Figures 3B,C.
To investigate PAM as a biomarker, we analyzed the scans
taken before the start of treatment. Namely, we investigated
the abdominal scan pairs whose scans were taken between 12
weeks prior and start of treatment. This resulted in 31 scan
pairs of 26 patients in the external validation set. Four patients
had multiple scan pairs. We aggregated multiple scan pairs per
patient by taking the average PAM prediction. This resulted in an
AUC of 0.70 (CI: 0.50–0.88, p = 0.054) for the prediction of 1
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year survival from the moment of start of treatment. Specificity
and sensitivity were 0.69 (CI: 0.50–0.87) and 0.82 (CI: 0.58–
1.00), respectively. Further analysis on PAM predicted survival
at baseline showed a significant difference of >464 days between
low- and high-risk patients (p = 0.012, log rank test), with the
high-risk group had a median survival of 266 days, and the
low-risk group did not reach median survival within the first 2
years of treatment. Combination of the abdominal and thoracic
scores (i.e., average) yielded a lower performance in terms of
classification (0.65 AUC, CI: 0.46–0.83, p = 0.118), and virtually
unchanged results for the survival analysis (p = 0.012, log-rank
test). The limited number of patients did not allow to explore
more advanced methods for score combinations.
Comparison With Current Monitoring
Standards
Univariate analysis for current monitoring standards showed
significant performance for both radiological assessments, as
well as laboratory (hemoglobine, erythrocytes, leukocytes, and
thrombocytes) results. Radiological progression and response
reached an AUC of 0.64 (CI: 0.58–0.70, p < 0.001) and 0.66 (CI:
0.62–0.69, p < 0.001), respectively. In terms of blood markers,
increases in erythrocyte counts (0.57 AUC, CI: 0.51–0.62, p =
0.019), hemoglobin (0.62 AUC, CI: 0.57–0.66, p < 0.001), and
leukocyte counts (0.55 AUC, CI: 0.49–0.61, p = 0.039) were all
significant. None of these markers performed better than PAM.
PAM performance remained statistically significant against these
other biomarkers using multivariate analysis. Other factors that
retained significance were radiological progression (p < 0.001),
leukocyte count (p = 0.023), and age (p = 0.006). Hemoglobin
and erytrocyten were displayed with a high correlation (0.92) and
were averaged together. Their average, along with radiological
response and thrombocyte count were not significant.
Results of both univariate and multivariate are presented in
Table 1 and Figure 3B.
Visual Analysis of Abdominal Heatmaps
Results from visual analysis were classified based on highlighted
areas (hotspots), and whether they were cancer lesions,
cancer-spread complications, therapy-induced complications, or
seemingly healthy tissue. If cancer lesions and cancer-spread or
therapy-induced complications were not covered by a hotspot,
these were flagged as coldspots. In total, N = 31 cases were
analyzed. Table 2 shows a summary of the results. A heatmap
example is shown in Figure 3D.
In the abdomen, primary bladder tumors (N = 13), involved
lymph nodes (N = 18) and liver metastases (N = 10) were
flagged as prognostic by the AI algorithm in most cases where
they were present—namely, hotspots in 85, 83, and 80% of cases,
respectively. Similar frequencies were observed for bone (N =
7) and peritoneal metastases (N = 7), having been flagged in
86 and 71% of cases. Rare occurrences of adrenal metastasis, as
well as abdominal wall metastasis and a ureter mass were also
found, both as hotspots and coldspots. Low occurrence was also
observed for cancer spread-related complications. These were
hydronephrosis (N = 5), ascites (N = 3) and pleural effusion
(N = 1). Hydronephrosis and ascites were highlighted in 4 and
2 cases, respectively. Far more common were hotspots observed
on seemingly healthy tissue, including the hip region (N = 27),
pelvic bone (N = 26), spine (N = 25), liver and bowels (N = 20),
kidneys (N = 17), and spleen (N = 16). It was further observed
that, in the large majority of cases, only part of the tissue would
be highlighted, but never the full organ.
Visual Analysis of Chest Heatmaps
In the thorax, 7 out of 11 lung lesions were highlighted (64%).
The mediastinum, chest wall, and upper spine were the most
common hotspots in seemingly healthy areas. Other lesion
types, such as lymph node metastases and bone metastases,
were also present but low in numbers. Observed cancer spread-
related complications include pleural effusion (hotspot in 1 out
of 2 cases), and ascites (coldspot). Pneumonitis and sarcoid-
like disease were also present as therapy-related complication
hotspots, but both as single cases. A summary of the results is
shown in Table 2.
DISCUSSION
Advanced and non-invasive imaging methods for evaluation of
treatment response, which would provide comprehensive and
reliable information on how the patient responds to treatment,
could improve accurate clinical decision making. Our aim was
to assess the prognostic value of AI-enriched thoraco-abdominal
CT response assessment in stage-IV urothelial cancer patients
undergoing immune checkpoint inhibitors. We set up a fully-
automatic AI-system that would track changes between follow-
up thoraco-abdominal CT scans, and linked their quantitative
descriptors to overall survival. We term this method prognostic
AI-monitor (PAM).
Our findings showed that PAM reached significant predictive
performance for both thoracic and abdominal CT, with AUCs of
0.67 and 0.73, respectively, for the prediction of 1-year overall
survival from the moment of the scan. In-depth analysis revealed
stark differences in the prognostic value of morphological
changes depending on the time point of treatment, with the first
9 months of treatment being the most predictive and significant
AUCs > 0.70, peaking to over 0.80 for both abdominal imaging,
and thoracic imaging. Similar findings were observed in our
previous study on NSCLC (8), where the changes recorded by the
algorithm in the first 3 to 5 months of treatment were observed to
have a higher prognostic value. In the present study, we extended
the system to include both the thorax and abdomen, and trained
with far larger datasets both in terms of pre-training as well as
survival association. The AI algorithm designed in this study was
significantly extended to a comprehensive AI-system (i.e., PAM),
able to scan imaging data, identify the regions of interests, and
analyze them for the purpose of monitoring and prognostication.
By including abdominal images, we also showed that the previous
system (8) can be extended to multiple parts of the human body.
To the best of our knowledge, this is one of the first
studies employing artificial intelligence for prognostication in
immunotherapy-treated urothelial cancer patients. In the study
by Park et al. (37), the authors developed a radiomics model
for the prediction of objective response and overall survival
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TABLE 1 | Prognostic performance of PAM against current monitoring tools.
Univariate analysis
N. negative/positive p-value ROC AUC (95 CI) Sensitivity Specificity
Erythrocyte count (1/dt) 358/110 0.019 0.57 (0.51–0.62)* 0.47 (0.43–0.52) 0.42 (0.34–0.49)
Hemoglobin (1/dt) 372/122 < 0.001 0.62 (0.57–0.66)* 0.47 (0.43–0.51) 0.38 (0.31–0.45)
Leukocyte count (1/dt) 366/116 0.039 0.55 (0.49–0.61) 0.52 (0.48–0.56) 0.56 (0.49–0.64)
Thrombocyte count (1/dt) 366/116 0.421 0.51 (0.45–0.56) 0.51 (0.47–0.56) 0.54 (0.46–0.61)
Radiological Progression 145/65 < 0.001 0.64 (0.58–0.70) 0.87 (0.82–0.91) 0.42 (0.31–0.52)
Radiological response 145/65 < 0.001 0.66 (0.62–0.69) * 0.69 (0.62–0.75) 0.00 (0.00–0.00)
AI-score (abdomen) 437/117 < 0.001 0.73 (0.69–0.76) 0.60 (0.56–0.64) 0.74 (0.69–0.80)
AI-score (thorax) 1,421/516 < 0.001 0.67 (0.64–0.69) 0.58 (0.56–0.60) 0.71 (0.68–0.74)
Multivariate analysis
Coefficient Standard deviation 95 Confidence interval p-value
Intercept −1.1010 3.213 −7.398 5.196 0.732
AI-score (abdomen) −7.9394 1.683 −11.239 −4.640 <0.001
Age −7.3906 2.699 −12.680 −2.101 0.006
Erythrocyte + hemoglobin (1/dt) −0.2210 2.455 −5.034 4.592 0.928
Leukocyte count (1/dt) 10.9735 4.810 1.546 20.401 0.023
Thrombocyte count (1/dt) −0.3935 2.022 −4.357 3.570 0.846
Radiological progression −3.0030 0.693 −4.361 −1.645 <0.001
Radiological response > 100 > 100 < −100 > 100 0.999
AUC < 0.5 were inverted for readability, indicated by *.
in a similar population. Machine learning was also employed
on imaging (radiomics) features, however these were extracted
via manually delineated lesions. The authors reported an AUC
of 0.88 (CI: 0.65–0.97) for objective response prediction of
bladder tumors in a cohort of N = 21 patients, with a
significant difference in overall survival between (radiomics-
identified) higher and lower risk groups. Our findings also
showed significant differences in survival, but in contrast to the
above study, we looked at the whole body changes, not only
those of the tumoral lesions but also the non-tumoral treatment-
or cancer-related changes (e.g., side-effects, organ compression,
etc.). Our results are comparable to state-of-the-art methods
based on time-consuming, error-prone, manual delineations (6,
7). Till now, single lesion analysis has allowed the field to develop,
however, it has restricted the usage of the image only to selected
areas-of-interest, accounting for<5% of the total data in the scan.
While these methods have been refined to leverage known factors
in cancer growth, including vascularity (38), oxygenation (39),
and metabolic activity (40)—our approach is different. Not only
do we offer a novel fully automatic procedure which completely
eradicates the need of time-consuming segmentations, but it also
makes use of the whole body image of the patient, to evaluate the
patient’s status and estimate survival.
We analyzed the PAM further, bymeans of visualization.More
specifically, we employed a visualization method (36) to generate
heatmaps, which highlighted regions of the image that carried
higher predictive value, according to PAM. In our case, hotspots
would correspond to gross morphological changes that the AI
algorithm deemed of prognostic relevance. An expert radiologist
was tasked to visually confirm these findings. Our findings show
that changes in the primary tumor of the bladder, as well as
metastases in lymph nodes, liver, peritoneum, and skeleton were
among the most predictive for the algorithm.
Interestingly, there are similarities between our results, and
the results from the NSCLC study (8). In both cases, the region
of the primary tumor, as well as lymph nodes and bone lesions
were closely inspected by the algorithm. Additionally, in the
present study, the algorithm is also tracking changes in liver
and peritoneal metastases. Unlike the present study however, the
AI in the NSCLC cohort was working only on chest imaging,
therefore unable to access the abdominal cavity.
There is evidence, in both studies, that bone lesions should
be accounted for in imaging evaluation schedules. These are
considered non-target lesions in the current response criteria and
are notoriously difficult to assess (4, 5, 41). Both bladder and lung
cancer generated evidence to support the further investigation for
the inclusion of CT changes in the bone among the target lesions.
Generally speaking, these findings suggest an unequal effect
of cancer lesions on survival. While this might seem trivial at
first (e.g., brain metastases are known to have worse prognosis),
all current imaging methods for response evaluation and
prognostication [like the RECISTs (4, 5, 41)] do not distinguish
between lesion types. RECIST methods are based on the change
in the sum of diameters of a (limited) set of lesions. In other
words, the growth of lesions in one organ is measured and
weighed in the same way as the growth of another lesion in
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TABLE 2 | Visual analysis of PAM generated prognostic maps.
Rare (<10%) 10–25% 25–50% Frequent (>50%)
Abdominal imaging
Hotspot tumor Lung mets (3), adrenal mets
(1), abdominal wall mets (1),
ureter (1), recurrence (2),
deposition (2)
Bone mets (6), peritoneal (5) Bladder Ca (11), lymph
nodes mets (16), liver mets
(8)
Hotspot tumor-related Ascites (2) Hydronephrosis (4)
Hotspot therapy-related
Hotspot healthy Pelvis (2), genital (3),
retroperitoneum (2)
Chest wall (7), pancreas (6) Abdominal wall (14),
stomach (13)
Bowel (21), liver (21), spleen
(17), kidneys (18), spine (26),
pelvic bone (27), hip region
(28)
Coldspot tumor Bladder Ca (2), lymph nodes
mets (3), lung mets (1), bone
mets (1), liver mets (2),
peritoneal mets (2), abdominal
wall mets (1), recurrence (1)
Coldspot tumor-related Pleural effusion (1), ascites (1),
hydronephrosis (1)
Chest imaging
Hotspot tumor Lymph nodes mets (3), bone
mets (2)
Lung mets (7), liver mets (4)
Hotspot tumor-related Pleural effusion (1)
Hotspot therapy-related Pneumonitis (1), sarcoid like
(2)
Hotspot healthy Lung (2) Mediastinum (25), chest wall
(27), upper abdomen (22),
spine (26)
Coldspot tumor Lymph nodes mets (3), lung
mets (4), bone mets (2), liver
mets (1)
Coldspot tumor-related Pleural effusion (1), ascites (1)
Ca, cancer; Mets, metastases. Number of cases between parenthesis (N).
a different organ—no distinction is made. Our results however
suggest that these factors should be accounted for, which would
therefore require a more comprehensive evaluation scheme.
In this study, we proposed a method that is based on image-
to-image registration, leveraging the properties of this technique
in finding corresponding anatomical landmarks in pairs of
images, and therefore constructing a model able to track not
only tumors but also tumor- and therapy induced changes, as
well as seemingly healthy parenchyma. Our method does not
preclude the usage of other techniques and methods. As we have
observed, commonly used clinical response evaluation tools also
retained significance when compared against PAM, suggesting
PAM as a complementary value to the current clinical standards.
An optimal approach to the utilization of PAM would be
integration of this method with other diagnostic tools currently
available (42).
The study was limited to whole-body CT, which is the
workhorse in standard clinical practice. As brain imaging is not
part of the standard whole-body CT protocol, anatomical and
functional changes in the brain as captured on MRI and PET/CT
are yet to be explored. We envision a more comprehensive usage
of this technique, where all available imaging during follow-
up is leveraged for prognostication purposes. It is also yet to
be confirmed whether the PAM approach would extend to
other treatments and cancer types, and to which extent survival
associations would be interchangeable. Further development of
PAM should also focus on pre-treatment scans. In this study,
we analyzed scans acquired up to 6 months before the start
of treatment. Some patients had to be excluded, as they lacked
follow-ups. We acknowledge that this could have introduced a
bias toward patients with extensive treatment history, or against
patients with the worse survival outcomes. An extension of PAM
to include more of the treatment history would be beneficial
in this sense, but it would require PAM to deal with the
plethora of all different treatments, and combinations thereof,
that nowadays oncological patients receive, hence beyond the
scope of this study.
Another limitation of the study is the monocentric nature
of the analysis. While CT data is generally acknowledged to
have higher level of reproducibility across vendors than MRI,
it is yet to be seen whether this would hamper the association
with survival, and to what extent. Nonetheless, we made sure
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to train the tracker and localizer modules on large publicly-
available datasets that would, in theory, provide a larger pool of
variations in image acquisition protocols. Future studies should
be focused on including a larger cohort of patients. This would
allow not only to increase the number of features used in
deformation modeling (now limited to 96), but also the machine
learning classifier used for predicting survival, which could in
turn increase the performance of the model.
Finally, the readers were, just like the algorithm, blinded to
the patient’s full-history. This did not allow them, for example,
to perform a complete RECIST assessment, which would require
the computation of a nadir. Further investigations should also
focus on a full-comparison of PAM and RECIST criteria (and
iRECIST), on whether they are complementary or mutually
exclusive, and what are the benefits of using one or the other.
As a future outlook, we envision an extended PAM-
like algorithm to be set up as a clinical decision support
system in tumor boards, providing continuous monitoring and
prognostication information, in order to assist physicians in the
treatment decision process.
CONCLUSIONS
In this study, we investigated the prognostic information
of AI-derived whole-body imaging monitoring markers in
advanced urothelial cancer receiving checkpoint inhibitors. We
hypothesized that quantitative AI-derived features describing
morphological changes happening during the course of treatment
could hold prognostic information. To this end, we designed
and implemented a prognostic AI-monitor (PAM). Our findings
demonstrate that PAM is complementary to existing monitoring
methods, while reaching comparable or superior accuracy. We
argue that this could be the result of PAM’s ability to analyze the
whole body, including non-target cancer lesions and non-cancer
lesions. Further investigation should focus on the development of
a comprehensive pipeline beyond anatomical imaging, as well as
on external validations.
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